Sobi's Tryngolza Receives EMA Validation for sHTG Treatment Indication Extension Sobi's Tryngolza has gained EMA validation for treating severe hypertriglyceridemia, marking a significant milestone in addressing patient needs.

Sobi's Tryngolza Receives EMA Validation for sHTG Treatment Indication Extension #Sweden #Stockholm #Sobi #Olezarsen #Tryngolza

Swedish Orphan Biovitrum AB (Sobi) Invites Shareholders to Annual General Meeting 2026 Sobi invites shareholders to attend the upcoming Annual General Meeting set for May 6, 2026, in Stockholm, Sweden. Key decisions will be made.

Swedish Orphan Biovitrum AB (Sobi) Invites Shareholders to Annual General Meeting 2026 #Sweden #AGM #Stockholm #Sobi

Notice of Annual General Meeting for Swedish Orphan Biovitrum AB: Key Details and Agenda The notice of the upcoming Annual General Meeting for Swedish Orphan Biovitrum AB outlines essential participant details and agenda items for stakeholders.

Notice of Annual General Meeting for Swedish Orphan Biovitrum AB: Key Details and Agenda #Sweden #Stockholm #Sobi #Annual_General_Meeting #Swedish_Orphan_Biovitrum

Sobi's Upcoming Capital Markets Day Promises Key Insights for Investors Join Sobi's Capital Markets Day on February 18, 2026, for critical updates on strategies and pipeline innovations directly from leadership.

Sobi's Upcoming Capital Markets Day Promises Key Insights for Investors #Sweden #Capital_Markets #Stockholm #Sobi

Sobi Strengthens Gout Treatment Options with Arthrosi Therapeutics Acquisition Sobi has finalized its acquisition of Arthrosi Therapeutics, enhancing its portfolio with a promising gout treatment, pozdeutinurad.

Sobi Strengthens Gout Treatment Options with Arthrosi Therapeutics Acquisition #Sweden #Stockholm #Sobi #gout #Arthrosi

Sobi reports strong fourth-quarter growth driven by its haematology portfolio. Revenue reached SEK 7,821 million, a 16% increase at CER, supported by sales of Altuvoct and Doptelet. #Sobi #lifescience

Sobi Reports Significant Growth and Strategic Advancements in 2025 Financial Year Sobi, a major biopharmaceutical firm, reveals impressive revenue growth and strategic accomplishments in its 2025 financial results, setting the stage for continued success.

Sobi Reports Significant Growth and Strategic Advancements in 2025 Financial Year #Sweden #Stockholm #Sobi #Altuvoct #Doptelet

Sobi Reports Strong Growth and Strategic Advancements in 2025 Financial Results Swedish Orphan Biovitrum AB presents its 2025 financial results, showcasing impressive revenue growth and strategic improvements in haematology and immunology sectors.

Sobi Reports Strong Growth and Strategic Advancements in 2025 Financial Results #Sweden #Stockholm #Sobi #Altuvoct #Doptelet

Sobi to Present Innovative Research and Commitment to Haemophilia at EAHAD 2026 Conference At the upcoming EAHAD 2026, Sobi will unveil new research on haemophilia treatments, emphasizing its dedication to advancing care for blood disorder patients.

Sobi to Present Innovative Research and Commitment to Haemophilia at EAHAD 2026 Conference #Sweden #Stockholm #Sobi #haemophilia #EAHAD

Sobi's Aspaveli® Secures European Commission Approval for C3G Treatment Sobi has announced the European Commission's approval of Aspaveli® for treating C3 glomerulopathy in patients aged 12 and above. This marks a major milestone in addressing rare kidney diseases.

Sobi's Aspaveli® Secures European Commission Approval for C3G Treatment #Sweden #Stockholm #Sobi #Aspaveli #C3G

Sobi's Anticipated Growth in 2025 Revenue and Adjusted EBITA Margin Exceeds Expectations Swedish Orphan Biovitrum AB announces significant growth in its 2025 revenue and adjusted EBITA margin, showcasing strong financial performance and positive projections ahead.

Sobi's Anticipated Growth in 2025 Revenue and Adjusted EBITA Margin Exceeds Expectations #Sweden #Stockholm #pharmaceuticals #Biopharma #Sobi

Sobi Reports Stronger-Than-Expected Performance for 2025 Financials Sobi has announced a significant increase in revenue and adjusted EBITA margin for the year 2025, surpassing previous projections and demonstrating robust growth.

Sobi Reports Stronger-Than-Expected Performance for 2025 Financials #Sweden #Stockholm #revenue_growth #Biopharma #Sobi

Sobi Announces Plans for Q4 and FY 2025 Financial Report Release Sobi is set to release its financial report for Q4 and the full year of 2025 on February 5, 2026, including a follow-up conference call for insights.

Sobi Announces Plans for Q4 and FY 2025 Financial Report Release #Sweden #Stockholm #2025 #Sobi #financial_report

Sobi's Gamifant® (emapalumab) Shows Promise in Sepsis Treatment Based on EMBRACE Study Results Sobi® announces significant findings from the EMBRACE study indicating Gamifant’s potential in treating interferon-gamma-driven sepsis, promising pathways for clinical development.

Sobi's Gamifant® (emapalumab) Shows Promise in Sepsis Treatment Based on EMBRACE Study Results #Sweden #Stockholm #Sobi #sepsis #Gamifant

#finanstwitter #aktier
15 största, 1 januari 2026, i storleksordning:
Sobi #SOBI
Investor #INVE
Plejd #PLEJD
Camurus #CAMX
Autoliv #ALIV
FlatexDEGIRO AG #FTK
Bonesupport #BONEX
NKT #NKT
Shelly Group Plc #SLYG
XTB #XTB
VEF #VEFAB
Essity #ESSITY
Elekta #EKTA
Bure #BURE
Ascelia Pharma #ACE

Sobi Announces Acquisition of Arthrosi Therapeutics to Enhance Gout Treatment Pipeline Sobi's acquisition of Arthrosi Therapeutics aims to boost innovation in gout treatments, particularly with the introduction of pozdeutinurad, a new oral therapy.

Sobi Announces Acquisition of Arthrosi Therapeutics to Enhance Gout Treatment Pipeline #None #Sobi #pozdeutinurad #Arthrosi

Sobi pays $1.5bn for Arthrosi to grow in gout Sobi has hit the acquisition trail with a deal to buy Arthrosi Therapeutics for up to $1.5 billion, adding a drug in late-stage testing for gout.

#Sobi has hit the #acquisition trail with a deal to buy #ArthrosiTherapeutics for up to $1.5 billion, adding a drug in late-stage clinical testing for #gout.

pharmaphorum.com/news/sobi-pa...

Viva Biotech's Arthrosi Enters $1.5 Billion Acquisition with Sobi Viva Biotech's Arthrosi Therapeutics has signed an acquisition agreement with Sobi worth up to $1.5 billion, enhancing gout treatment options.

Viva Biotech's Arthrosi Enters $1.5 Billion Acquisition with Sobi #Sweden #Stockholm #Sobi #Viva_Biotech #Arthrosi

Viva Biotech's Arthrosi Enters $1.5 Billion Acquisition Deal with Sobi Viva Biotech's incubated company, Arthrosi, has made headlines with its significant acquisition agreement with Sobi worth up to $1.5 billion.

Viva Biotech's Arthrosi Enters $1.5 Billion Acquisition Deal with Sobi #None #Sobi #Viva_Biotech #Arthrosi

Utan kontext låter det som att Beyfortus “pikar” i Q3 2025. Men Beyfortus är en säsongsprodukt – att lyfta Q3-royaltyn utan att nämna säsongseffekterna blir ganska missvisande. #SOBI

Sobi's Commitment to Advancing Haematology Highlighted at ASH 2025 Annual Meeting Sobi showcases its dedication to haematology with 19 scientific abstracts at the ASH 2025 meeting, addressing rare blood disorders and innovative treatments.

Sobi's Commitment to Advancing Haematology Highlighted at ASH 2025 Annual Meeting #Sweden #Stockholm #Sobi #Haematology #ASH_2025

#finanstwitter #aktier
15 största, 1 december 2025, i storleksordning:
Sobi #SOBI
Plejd #PLEJD
Investor #INVE
Camurus #CAMX
NKT #NKT
Autoliv #ALIV
Bonesupport #BONEX
FlatexDEGIRO AG #FTKd
Shelly Group Plc #SLYGd
VEF #VEFAB
XTB #XTB
Essity #ESSITY
Elekta #EKTA
Bure #BURE
Ascelia Pharma #ACE

Sobi’s Olezarsen Shows Promising Results for Treating Severe Hypertriglyceridemia A pivotal study of olezarsen presented at the AHA reveals significant benefits in treating severe hypertriglyceridemia, notably reducing acute pancreatitis events.

Sobi’s Olezarsen Shows Promising Results for Treating Severe Hypertriglyceridemia #Sweden #Stockholm #Sobi #Olezarsen #sHTG

Sobi to Showcase New Insights on pegcetacoplan at ASN Kidney Week 2025 Sobi will present compelling new data on the efficacy of pegcetacoplan for C3G and primary IC-MPGN during ASN Kidney Week 2025 in Houston, Texas.

Sobi to Showcase New Insights on pegcetacoplan at ASN Kidney Week 2025 #United_States #Houston #Sobi #ASN_Kidney_Week #pegcetacoplan

#finanstwitter #aktier
15 största, 1 november 2025, i storleksordning:
Plejd #PLEJD
Sobi #SOBI
Investor #INVE
Camurus #CAMX
Bonesupport #BONEX
NKT #NKT
FlatexDEGIRO AG #FTKd
VEF #VEFAB
ALK-Abelló #ALK
Autoliv #ALIV #ALV
Shelly Group Plc #SFLYG
Essity #ESSITY
Elekta #EKTA
Orion #ORNBV
Bure #BURE

Sobi Unveils Novel Findings on Rare Inflammatory Disorders at ACR 2025 Sobi presents groundbreaking data on rare inflammatory diseases at ACR 2025, highlighting advancements in treatments for uncontrolled gout and other conditions.

Sobi Unveils Novel Findings on Rare Inflammatory Disorders at ACR 2025 #Sweden #Stockholm #Sobi #ACR #emapalumab

Släppte Dynavox #DYVOX
Ökat i Sobi #SOBI istället

24. Startskott rapportsäsong – bolagen att hålla koll på, oväntade VD-avhopp & nya härvor?

Avsnitt 24 ute!

Rapportsäsongen är igång och vi river av SOBI och nätmäklarna (Avanza/Nordnet/Flatex). Björn noterar intensiteten i Novos nyhetsflöde och vi reder även i Playtech/Evo-härvan.

Lyssna in!

#AZA #SAVE #FTKd #SOBI #LULU #Q3 #pratapengar

Significant Change in Sobi's Board of Directors: Helena Saxon Steps Down Sobi, a leading biopharmaceutical company, announces the resignation of Helena Saxon from its board, effective immediately. Learn more about her contributions.

Significant Change in Sobi's Board of Directors: Helena Saxon Steps Down #Sweden #Stockholm #Biopharmaceutical #Sobi #Helena_Saxon

Sobi Board of Directors Sees Recent Change as Helena Saxon Resigns Helena Saxon has stepped down from Sobi's Board of Directors, effective immediately. Her extensive contributions since 2011 have greatly shaped the company's strategies.

Sobi Board of Directors Sees Recent Change as Helena Saxon Resigns #Sweden #Stockholm #Board_of_Directors #Sobi #Helena_Saxon